Statement before the Senate Committee on Health, Education, Labor and Pensions on the Enhancing Drug Safety and Innovation Act of 2006

We believe the Committee would miss a great opportunity for protecting consumer safety, however, if you don’t strengthen the bill in several key areas: assuring quicker publication of the results of more clinical drug trials; enhancing the FDA’s power to protect public health; restoring the science-based culture and morale of the FDA ; garnering more resources, especially for post-approval safety and information technology; and reforming the generic and biogeneric laws to bring lower-cost medicines to patients.